[go: up one dir, main page]

WO2007016153A3 - Tilmicosin formulation - Google Patents

Tilmicosin formulation Download PDF

Info

Publication number
WO2007016153A3
WO2007016153A3 PCT/US2006/029000 US2006029000W WO2007016153A3 WO 2007016153 A3 WO2007016153 A3 WO 2007016153A3 US 2006029000 W US2006029000 W US 2006029000W WO 2007016153 A3 WO2007016153 A3 WO 2007016153A3
Authority
WO
WIPO (PCT)
Prior art keywords
tilmicosin
formulation
tilmicosin formulation
same
calcium
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2006/029000
Other languages
French (fr)
Other versions
WO2007016153A2 (en
Inventor
Paul Reuben Klink
Robin Shane Readnour
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of WO2007016153A2 publication Critical patent/WO2007016153A2/en
Publication of WO2007016153A3 publication Critical patent/WO2007016153A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides an injectable formulation comprising tilmicosin, calcium and a liquid vehicle, methods of using the same, and processes for preparing the same.
PCT/US2006/029000 2005-07-28 2006-07-26 Tilmicosin formulation Ceased WO2007016153A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US70313905P 2005-07-28 2005-07-28
US60/703,139 2005-07-28
US75632406P 2006-01-05 2006-01-05
US60/756,324 2006-01-05

Publications (2)

Publication Number Publication Date
WO2007016153A2 WO2007016153A2 (en) 2007-02-08
WO2007016153A3 true WO2007016153A3 (en) 2007-04-19

Family

ID=37671225

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/029000 Ceased WO2007016153A2 (en) 2005-07-28 2006-07-26 Tilmicosin formulation

Country Status (1)

Country Link
WO (1) WO2007016153A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8143319B2 (en) 2006-07-18 2012-03-27 The Regents Of The University Of California Method and apparatus for steam hydro-gasification with increased conversion times
CN104906039B (en) * 2015-06-29 2018-07-03 湖南泰谷生物科技股份有限公司 A kind of Tilmicosin suspension and preparation method thereof
CN109464413A (en) * 2018-12-04 2019-03-15 中牧实业股份有限公司黄冈动物药品厂 A kind of Tilmicosin pellet and preparation method thereof
CN114796108B (en) * 2022-06-30 2022-09-02 山东国邦药业有限公司 Tilmicosin solution and preparation method thereof
CN116869929A (en) * 2023-07-11 2023-10-13 湖南绿亨世源动物药业有限公司 A kind of tilmicosin injection and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130211A1 (en) * 2001-10-19 2003-07-10 Murthy Yerramilli V.S.N. Injectable compositions for the controlled delivery of pharmacologically active compound

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030130211A1 (en) * 2001-10-19 2003-07-10 Murthy Yerramilli V.S.N. Injectable compositions for the controlled delivery of pharmacologically active compound

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; November 2000 (2000-11-01), SAKURAI HARUHIKO ET AL: "Cardiogenic shock triggered by verapamil and atenolol: A case report of therapeutic experience with intravenous calcium", XP002419159, Database accession no. PREV200000543182 *
HACK J B ET AL: "Pilot study: Use of calcium chloride to treat hyperkalemia due to acute digoxin toxicity in a swine model.", JOURNAL OF TOXICOLOGY CLINICAL TOXICOLOGY, vol. 41, no. 5, August 2003 (2003-08-01), & ANNUAL MEETING OF THE NORTH AMERICAN CONGRESS OF CLINICAL TOXICOLOGY; CHICAGO, IL, USA; SEPTEMBER 04-09, 2003, pages 696, XP009078256, ISSN: 0731-3810 *
PORTER J M ET AL: "The efficacy of nicorandil, calcium chloride and nitroglycerin in treatment of ropivacaine-induced cardiotoxicity.", EUROPEAN JOURNAL OF ANAESTHESIOLOGY, vol. 20, no. 12, December 2003 (2003-12-01), pages 939 - 944, XP009078234, ISSN: 0265-0215 *

Also Published As

Publication number Publication date
WO2007016153A2 (en) 2007-02-08

Similar Documents

Publication Publication Date Title
WO2008070269A3 (en) Methods, software and systems for imaging
WO2006116348A3 (en) Compositions for medical devices containing agent combinations in controlled volumes
WO2007133290A3 (en) Anti-ox40l antibodies and methods using same
WO2008060705A3 (en) Anti-dll4 antibodies and methods using same
WO2009152276A3 (en) Photoacid generators and lithographic resists comprising the same
IL184175A (en) Sulfonyl pyrrolidines, method for producing the same and their use as drugs
EG25348A (en) Process for the manufacture of diesel range hydrocarbons.
WO2007076062A3 (en) Protein formulations with reduced viscosity and uses thereof
IL214183A (en) Pharma-informatics system and method, composition for use therewith and method of preparing the composition
WO2005041752A3 (en) Bone plate and method for using bone plate
WO2007024705A3 (en) Method of treating depression using a tnf-alpha antibody
WO2008100805A3 (en) Anti-robo4 antibodies and uses therefor
WO2008054676A3 (en) Medical devices and methods of using the same
PL1954745T3 (en) Adhesive formulation, method for the production thereof, and use thereof
WO2009058379A3 (en) Protein scaffolds
WO2010077898A3 (en) Trans-chloro-3,3,3-trifluoropropene for use in chiller applications
WO2007047781A3 (en) Hydrophobic cross-linked gels for bioabsorbable drug carrier coatings
WO2007067469A3 (en) Method for expelling gas positioned between a substrate and a mold
WO2006124713A3 (en) 4-biarylyl-1-phenylazetidin-2-ones
WO2006083936A3 (en) Anti-ephb2 antibodies and methods using same
WO2007076174A3 (en) Methods, systems, and apparatus for multi-domain markers
WO2007011741A3 (en) Stable organic devices
EP1733932B8 (en) Airbag, method of manufacturing the same, airbag apparatus and vehicle
WO2009146099A3 (en) Contrast agents, methods for preparing contrast agents, and methods of imaging
WO2005074645A3 (en) Methods and compositions for modulating angiogenesis

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06788537

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06788537

Country of ref document: EP

Kind code of ref document: A2